GlassScriptPhysician profile
Rajvinder Parmar
NPI 1609038348
$7,133.30
in general payments reported to CMS, 2019-2025
49 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $630 · 2021: $676 · 2022: $801 · 2023: $1,218 · 2024: $1,447 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,123.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $697.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $608.43 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $563.83 | 2021-2025 | |
| Novo Nordisk INC | $526.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $482.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $382.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $359.97 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $322.22 | 2022-2025 | |
| Astellas Pharma US INC | $267.17 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.38 | 2021-2024 | Ofev, Jardiance, Tradjenta |
| Abbott Laboratories | $220.56 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $205.64 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $193.77 | 2019-2025 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $192.35 | 2021-2024 | Austedo Xr, Airduo Digihaler |
| Exact Sciences Corporation | $155.90 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajvinder Parmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.